-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Merck & Co. Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$41.52B | $48.70B | $59.28B | $60.12B |
| Cost of Revenue |
|
$13.62B | $13.63B | $17.41B | $16.13B |
| Gross Profit |
|
$27.90B | $35.08B | $41.87B | $43.99B |
| Research & Development |
|
$13.40B | $12.25B | $13.55B | $30.53B |
| Selling,General & Administrative |
|
$8.96B | $9.63B | $10.04B | $10.50B |
| Operating Expense |
|
$22.35B | $21.88B | $23.59B | $40.91B |
| Operating Income |
|
$6.08B | $13.70B | $19.40B | $2.95B |
| Net Income |
|
$7.07B | $13.05B | $14.52B | $365.00M |
Merck & Co. Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.06B | $8.10B | $13.19B | $7.09B |
| Inventories |
|
$6.31B | $5.95B | $5.91B | $6.36B |
| Total Current Assets |
|
$27.76B | $30.27B | $35.72B | $32.17B |
| Property,Plant and Equipment |
|
$17.99B | $19.28B | $21.42B | $24.49B |
| Goodwill |
|
$20.24B | $21.26B | $21.20B | $21.20B |
| Total Assets |
|
$91.59B | $105.69B | $109.16B | $106.68B |
| Total Liabilities |
|
$66.18B | $67.44B | $63.10B | $69.04B |
| Retained Earnings |
|
$47.36B | $53.70B | $61.08B | $53.90B |
| Total Shareholder Equity |
|
$25.32B | $38.18B | $45.99B | $37.58B |
| Common Stock |
|
$1.79B | $1.79B | $1.79B | $1.79B |
Merck & Co. Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.63B | $3.21B | $3.91B | $3.87B |
| Dividends Payout |
|
-$6.22B | -$6.61B | -$7.01B | -$7.45B |
| Capital Expenditures (Capex) |
|
-$4.68B | -$4.45B | -$4.39B | -$3.86B |
| Free Cash Flow (FCF) |
|
$5.57B | $9.66B | $14.71B | $9.14B |
Merck & Co. Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$27.90B | $35.08B | $41.87B | $43.99B |
| Gross Profit Margin (%) |
|
67.20% | 72.02% | 70.63% | 73.17% |
| Operating Income |
|
$6.08B | $13.70B | $19.40B | $2.95B |
| Operating Income Margin (%) |
|
14.63% | 28.14% | 32.72% | 4.91% |
| Net Income |
|
$7.07B | $13.05B | $14.52B | $365.00M |
| Net Income Margin (%) |
|
17.02% | 26.79% | 24.49% | 0.61% |
| EBITDA |
|
$10.18B | $17.90B | $21.32B | $6.91B |
| EBITDA Margin (%) |
|
23.03% | 34.73% | 39.32% | 11.49% |
Merck & Co. Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
27.91% | 34.17% | 31.57% | 0.97% |
| Return on Assets (ROA) |
|
7.72% | 12.35% | 13.30% | 0.34% |
| Debt to Equity |
|
125.57% | 86.69% | 66.73% | 93.28% |
| Debt to total asset |
|
34.71% | 31.32% | 28.12% | 32.86% |
| Enterprise value to revenue |
|
5.32 | 4.49 | 5.04 | 5.22 |
| Enterprise value to EBITDA |
|
21.72 | 12.23 | 14.02 | 45.41 |
| Enterprise value |
|
$221.07B | $218.91B | $298.92B | $313.66B |
| Cash to Debt |
|
32.25% | 42.62% | 62.22% | 37.10% |
| Tax Rate (%) |
|
19.44% | 10.96% | 11.66% | 80.04% |
| Payout Ratio |
|
87.94% | 50.66% | 48.30% | 2,039.73% |
Related company
